Next Article in Journal
Nitric Oxide Synthase Inhibitors as Antidepressants
Next Article in Special Issue
In Response to: ‘Impact of Glycosylation on Effector Functions of Therapeutic IgG’ (Pharmaceuticals 2010, 3, 146–157)
Previous Article in Journal
Antihypertensive Peptides from Milk Proteins
Previous Article in Special Issue
Impact of Glycosylation on Effector Functions of Therapeutic IgG
Open AccessReview

Monoclonal Antibodies for Systemic Lupus Erythematosus (SLE)

1
Division of Nephrology, Scientific Institute Humanitas, via Manzoni 56, 20089 Rozzano (Milano), Italy
2
Division of Nephrology, Scientific Institute Ospedale Maggiore, Milano, Italy
*
Author to whom correspondence should be addressed.
This paper belongs to the Special Issue “Monoclonal Antibody”, edited by Jagadeesh Bayry.
Pharmaceuticals 2010, 3(1), 300-322; https://doi.org/10.3390/ph3010300
Received: 3 December 2009 / Revised: 12 January 2010 / Accepted: 15 January 2010 / Published: 20 January 2010
(This article belongs to the Special Issue Monoclonal Antibody)
A number of monoclonal antibodies (mAb) are now under investigation in clinical trials to assess their potential role in Systemic Lupus Erythematosus (SLE). The most frequently used mAb is rituximab, which is directed against CD20, a membrane protein expressed on B lymphocytes. Uncontrolled trials reported an improvement of SLE activity in non-renal patients and other studies even reported an improvement of severe lupus nephritis unresponsive to conventional treatments. However two randomized trials failed to show the superiority of rituximab over conventional treatment in non renal SLE and in lupus nephritis. Preliminary trials reported promising results with epratuzumab, a humanized mAb directed against CD22, and with belimumab, a human mAb that specifically recognizes and inhibits the biological activity of BLyS a cytokine of the tumornecrosis-factor (TNF) ligand superfamily. Other clinical trials with mAb directed against TNF-alpha, interleukin-10 (Il-10), Il-6, CD154, CD40 ligand, IL-18 or complement component C5 are under way. At present, however, in spite of good results reported by some studies, no firm conclusion on the risk-benefit profile of these mAbs in patients with SLE can be drawn from the available studies. View Full-Text
Keywords: systemic lupus erythematosus; lupus nephritis; monoclonal antibodies; rituximab systemic lupus erythematosus; lupus nephritis; monoclonal antibodies; rituximab
MDPI and ACS Style

Ponticelli, C.; Moroni, G. Monoclonal Antibodies for Systemic Lupus Erythematosus (SLE). Pharmaceuticals 2010, 3, 300-322.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop